Orthofix Medical (OFIX) Expected to Announce Earnings on Tuesday

Orthofix Medical (NASDAQ:OFIX) is expected to be posting its Q1 2026 results before the market opens on Tuesday, May 5th. Analysts expect Orthofix Medical to post earnings of ($0.29) per share and revenue of $193.2750 million for the quarter. Individuals can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Tuesday, May 5, 2026 at 8:30 AM ET.

Orthofix Medical (NASDAQ:OFIX) last released its quarterly earnings data on Saturday, February 14th. The medical device company reported ($0.06) earnings per share for the quarter. Orthofix Medical had a negative net margin of 11.21% and a negative return on equity of 20.38%. The company had revenue of $219.91 million for the quarter. On average, analysts expect Orthofix Medical to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Orthofix Medical Price Performance

OFIX opened at $11.91 on Monday. The company has a quick ratio of 1.43, a current ratio of 2.45 and a debt-to-equity ratio of 0.39. The firm has a 50 day moving average price of $12.27 and a 200-day moving average price of $13.95. Orthofix Medical has a twelve month low of $10.24 and a twelve month high of $16.99. The stock has a market capitalization of $478.07 million, a price-to-earnings ratio of -5.09 and a beta of 0.79.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the stock. Barrington Research reissued an “outperform” rating and set a $17.00 price objective on shares of Orthofix Medical in a report on Friday, April 10th. TD Cowen assumed coverage on shares of Orthofix Medical in a report on Tuesday, January 27th. They set a “hold” rating and a $14.00 price objective for the company. Canaccord Genuity Group decreased their price objective on shares of Orthofix Medical from $24.00 to $20.00 and set a “buy” rating for the company in a report on Thursday, February 26th. Weiss Ratings reissued a “sell (d-)” rating on shares of Orthofix Medical in a report on Tuesday, April 21st. Finally, Wall Street Zen cut shares of Orthofix Medical from a “buy” rating to a “hold” rating in a report on Saturday. Three research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Orthofix Medical currently has a consensus rating of “Hold” and a consensus target price of $17.25.

Insider Buying and Selling at Orthofix Medical

In other Orthofix Medical news, insider Jorge Andres Cedron sold 3,743 shares of the business’s stock in a transaction dated Thursday, April 16th. The stock was sold at an average price of $12.82, for a total transaction of $47,985.26. Following the completion of the sale, the insider owned 59,006 shares of the company’s stock, valued at approximately $756,456.92. The trade was a 5.97% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, major shareholder Engine Capital Management, Lp purchased 13,061 shares of the business’s stock in a transaction on Wednesday, February 25th. The shares were bought at an average cost of $12.96 per share, with a total value of $169,270.56. Following the acquisition, the insider directly owned 3,673,092 shares of the company’s stock, valued at $47,603,272.32. This trade represents a 0.36% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. 1.30% of the stock is currently owned by corporate insiders.

Institutional Trading of Orthofix Medical

Hedge funds have recently bought and sold shares of the stock. AQR Capital Management LLC boosted its position in shares of Orthofix Medical by 67.7% in the first quarter. AQR Capital Management LLC now owns 20,409 shares of the medical device company’s stock worth $333,000 after purchasing an additional 8,241 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Orthofix Medical by 6.3% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,561 shares of the medical device company’s stock worth $335,000 after purchasing an additional 1,213 shares during the period. Jane Street Group LLC bought a new position in shares of Orthofix Medical in the first quarter worth approximately $1,076,000. Strs Ohio bought a new position in shares of Orthofix Medical in the first quarter worth approximately $150,000. Finally, JPMorgan Chase & Co. boosted its position in shares of Orthofix Medical by 15.6% in the second quarter. JPMorgan Chase & Co. now owns 193,549 shares of the medical device company’s stock worth $2,158,000 after purchasing an additional 26,123 shares during the period. Institutional investors own 89.76% of the company’s stock.

About Orthofix Medical

Orthofix Medical Inc (NASDAQ: OFIX) is a global medical device company focused on the design and development of innovative orthopedic and spinal solutions. The company’s core business is divided into two segments: spine and orthopedics. In the spine segment, Orthofix offers a range of titanium implants, biologics and portable bone growth stimulation devices designed to support spinal fusion, deformity correction and minimally invasive procedures. Its orthopedic segment encompasses products for fracture fixation, external fixation systems, trauma care and sports medicine, providing surgeons with implantable devices and instruments for complex bone reconstruction and healing.

Orthofix’s product portfolio includes strut systems, bone growth stimulators, interbody fusion devices and fixation hardware that address various indications such as degenerative disc disease, spinal deformities, non-unions and long-bone fractures.